69 patents
Utility
KIR3DL2 binding agents
2 Jan 24
The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2.
Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
Filed: 28 Feb 20
Utility
MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123
28 Dec 23
Marielle CHIRON, Angela Virone-Oddos, Laurent Gauthier
Filed: 28 Apr 23
Utility
NKp46 binding proteins
19 Dec 23
Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells.
Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
Filed: 8 Nov 19
Utility
Compositions and Methods for Treating Cancer
26 Oct 23
The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39.
Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
Filed: 13 Feb 23
Utility
Subcutaneous ANTI-C5AR Antagonist Treatment Regimen with Avdoralimab
26 Oct 23
The present invention concerns therapeutic uses of C5aR antagonists, particularly avdoralimab, in particular in relation to chronic inflammatory or autoimmune disorders, and in particular in inflammatory skin diseases.
CARINE PATUREL
Filed: 6 Aug 21
Utility
Treatment of head and neck cancer
24 Oct 23
This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab.
Agnes Boyer-Chammard, Pierre Dodion, Roger Cohen
Filed: 12 Mar 19
Utility
Neutralization of Inhibitory Pathways In Lymphocytes
28 Sep 23
This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
Filed: 9 Jun 23
Utility
Cell Surface Mica and Micb Detection Using Antibodies
21 Sep 23
The present disclosure relates to research and diagnostic tools to specifically detect MICA and MICB polypeptides in paraffin embedded tissue samples.
MARION BENEZECH, ROMAIN REMARK
Filed: 6 Aug 21
Utility
Neutralization of Inhibitory Pathways In Lymphocytes
27 Jul 23
The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1.
PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
Filed: 6 Feb 23
Utility
Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123
4 Jul 23
Marielle Chiron, Angela Virone-Oddos, Laurent Gauthier
Filed: 30 Dec 21
Utility
Siglec-9-neutralizing antibodies
11 Apr 23
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec.
Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
Filed: 9 Jul 18
Utility
Restoration of T Cell Activity Via the CD39/CD73 Axis
30 Mar 23
The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
Filed: 28 Jul 22
Utility
Treatment of Cancer
30 Mar 23
The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells.
MANEL KRAIEM
Filed: 28 Jan 21
Utility
Combination Therapy Using Antibody to Human SIGLEC-9 and Antibody to Human NKG2A for Treating Cancer
23 Mar 23
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec.
STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
Filed: 19 Sep 22
Utility
Compositions and methods for treating cancer
14 Feb 23
The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39.
Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
Filed: 16 Mar 18
Utility
Neutralization of inhibitory pathways in lymphocytes
7 Feb 23
The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1.
Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
Filed: 9 Jul 20
Utility
Compositions and Methods for Treating Cancer
26 Jan 23
The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39.
Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
Filed: 30 Jun 22
Utility
NKp46 BINDING AGENTS
27 Oct 22
The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides.
NADIA ANCERIZ, MATHIEU BLERY, LAURENT GAUTHIER, CARINE PATUREL
Filed: 29 Jun 22
Utility
Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
20 Sep 22
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec.
Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann
Filed: 9 Jul 18
Utility
NKp46 binding agents
5 Jul 22
The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides.
Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
Filed: 22 Jan 18